(I) Construction project name: Construction project of Minhai Biological New Vaccine International Industrial Base (Phase I)

 

(2) Location: Daxing Biomedical Industrial Base, Daxing District, Zhongguancun Science and Technology Park, Daxing District, Beijing, 053-039, 040, 043, 044, east to Tianfu Street, south to the planned land boundary, west to Xiangrui Street, north to Si Miao Road.

 

(3) Construction content: The project uses a scale of 90013.218m2, above-ground building scale of 135020m2; floor area ratio of 1.5; building density of 40%; green space ratio of 15%; controlled height of 36 meters. Annual production of 20 million doses of combined cell-free leukoplakia inactivated poliomyelitis and Haemophilus influenzae type b vaccine; 25 million doses of pneumococcal conjugate vaccine; Mabella varicella series vaccine: Mabira combined attenuated live vaccine Agent, 5 million doses of attenuated live attenuated varicella and chickenpox vaccine, and 10 million doses of lyophilized live attenuated varicella vaccine.

 

(4) Name of construction unit: Beijing Minhai Biological Technology Co., Ltd.

 

Contact: Xia Zhanxiong

 

Telephone: 010-59613634

 

Email: xiazhanxiong@biominhai.com

 

(5) Compiling unit of environmental impact report: Puhua Holdings Co., Ltd.

 

(6) Web link for public comment form: http://www.biominhai.com/xwzx_xi/newsId=347.html

 

(7) Ways and means of submitting public comment forms.

 

Phone: 010-59613634

 

Email: xiazhanxiong@biominhai.com

 

In the process of preparing the draft of the environmental impact report, the public can submit opinions related to the environmental impact assessment to the construction unit.